Larson Financial Group LLC Trims Stake in Eli Lilly and Company (NYSE:LLY)

Larson Financial Group LLC reduced its position in Eli Lilly and Company (NYSE:LLY) by 2.0% during the third quarter, HoldingsChannel.com reports. The firm owned 14,844 shares of the company’s stock after selling 300 shares during the period. Eli Lilly and Company makes up 0.7% of Larson Financial Group LLC’s portfolio, making the stock its 29th biggest position. Larson Financial Group LLC’s holdings in Eli Lilly and Company were worth $13,151,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Earnest Partners LLC raised its stake in Eli Lilly and Company by 13.8% in the first quarter. Earnest Partners LLC now owns 453 shares of the company’s stock worth $352,000 after buying an additional 55 shares in the last quarter. Caxton Associates LP bought a new position in shares of Eli Lilly and Company during the 1st quarter worth approximately $3,659,000. Zurich Insurance Group Ltd FI boosted its position in shares of Eli Lilly and Company by 2.5% in the 1st quarter. Zurich Insurance Group Ltd FI now owns 234,898 shares of the company’s stock worth $182,741,000 after purchasing an additional 5,719 shares in the last quarter. Captrust Financial Advisors increased its holdings in shares of Eli Lilly and Company by 95.8% during the first quarter. Captrust Financial Advisors now owns 598,834 shares of the company’s stock valued at $465,869,000 after acquiring an additional 293,050 shares in the last quarter. Finally, Kinloch Capital LLC grew its holdings in shares of Eli Lilly and Company by 59.5% during the first quarter. Kinloch Capital LLC now owns 909 shares of the company’s stock valued at $707,000 after buying an additional 339 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Down 0.3 %

Shares of LLY stock opened at $748.01 on Friday. Eli Lilly and Company has a 1 year low of $561.65 and a 1 year high of $972.53. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The firm has a market capitalization of $710.10 billion, a PE ratio of 80.87, a price-to-earnings-growth ratio of 2.84 and a beta of 0.43. The stock has a fifty day moving average of $865.01 and a two-hundred day moving average of $869.65.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. During the same period in the prior year, the company earned $0.10 earnings per share. The company’s revenue for the quarter was up 20.4% on a year-over-year basis. As a group, research analysts expect that Eli Lilly and Company will post 13.2 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be given a dividend of $1.30 per share. The ex-dividend date is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.70%. Eli Lilly and Company’s payout ratio is currently 56.22%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Guggenheim boosted their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Berenberg Bank upped their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Truist Financial raised their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Finally, Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,007.94.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.